

### Company In-Depth

20 October 2006 | 11 pages

## Reliance Industries (RELI.BO)

### 2QFY07: Quarter of Role Reversals

- 2Q materially above expectations RIL's EBITDA growth of 7.7% qoq and 23.0% yoy was ahead of expectations as petrochemicals provided the incremental upside, led by improved volumes and margins across the board. Net profit as a result was up 9.2% yoy and 6.3% qoq.
- Petchem had everything going well High utilization of recently commissioned capacities, robust product spreads and recovery from 1Q cracker shutdown combined to deliver the highest ever EBIT contribution, with margins expanding 510bps qoq. Though we view delay in Middle East capacity additions as a positive, such strength may not get repeated in the short term.
- Refining Not great as expected While GRM at US\$9.1/bbl was down, the qoq
  decline was cushioned by lower retail losses and the unexpected absence of stock
  losses. Despite higher throughput, refining EBIT was down Rs5.5bn on qoq basis.
- More details on KG shortly In the Analyst Meet, management indicated that the revised development capex and production target of KG D-6 will be disclosed in next 3-4 months. Capex is likely to be 2x the initial estimate, in line with the US\$5bn factored in our NAV. Reliance also disclosed gas discovery in a new field (KG III 5), which has been notified to DGH.
- Earnings upped but new businesses more critical for the stock While higher earnings estimate for FY07-08 (upped 3.0-4.0%) could form a support for the stock, new businesses remain nascent for any meaningful value accretion equity investment in Reliance Retail was Rs4.0bn during 1H and Rs6.5bn cumulative and rollout will be visible gradually from 3Q onwards. Maintain Hold/Low Risk.

See page 9 for Analyst Certification and important disclosures.

Statistical Abstract							
Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/CEPS	EV/EBITDA	ROE
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(x)	(%)
2005A	75,717	54.34	43.0	22.0	14.8	14.8	20.3
2006A	90,693	65.10	19.8	18.4	13.4	12.4	26.4
2007E	101,866	73.12	12.3	16.4	11.8	11.1	31.0
2008E	101,190	72.64	-0.7	16.5	12.2	11.1	24.4
2009E	111,233	79.85	9.9	15.0	10.7	9.8	22.0


Rating change □

Target price change □

Estimate change 🗹

Hold/Low Risk	2L
Price (19 Oct 06)	Rs1,195.65
Target price	Rs1,150.00
Expected share price return	-3.8%
Expected dividend yield	0.8%
Expected total return	-3.0%
Market Cap	Rs1,666,148M
	US\$36,780M

## Price Performance (RIC: RELI.BO, BB: RIL IN)



### Rahul Singh<sup>1</sup>

+91-22-5631-9863 rahul.r.singh@citigroup.com

#### Pradeep Mirchandani, CFA1

+91-22-5631-9877

pradeep.mirchandani@citigroup.com

Saurabh Handa<sup>1</sup>

saurabh.handa@citigroup.com

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report, and who may be associated persons of the member or member organization, are not registered/qualified as research analysts with the NYSE and/or NASD, but instead have satisfied the registration/qualification requirements or other research-related standards of a non-US jurisdiction.

Source: Company Reports and Citigroup Investment Research

<sup>&</sup>lt;sup>1</sup>Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2005	2006	2007E	2008E	2009E
Valuation Ratios					
P/E adjusted (x)	22.0	18.4	16.4	16.5	15.0
EV/EBITDA adjusted (x)	13.0	11.9	10.6	10.4	9.1
P/BV (x)	4.1	5.8	4.5	3.6	3.0
Dividend yield (%)	0.6	0.8	0.8	8.0	0.9
Per Share Data (Rs)					
EPS (adjusted)	54.34	65.10	73.12	72.64	79.85
EPS (reported)	54.34	65.10	73.12	72.64	79.85
BVPS	288.75	205.28	267.15	328.54	396.01
DPS	7.50	10.00	10.00	10.00	11.00
Profit & Loss (RsM)					
Net sales	660,513	812,113	1,093,525	1,014,355	971,840
Operating expenses	-571,173	-702,072	-964,339	-883,449	-835,428
EBIT	89,340	110,041	129,186	130,906	136,412
Net interest expense	-14,687	-8,770	-10,373	-11,217	-10,498
Non-operating/exceptionals	16,034	5,770	4,661	6,799	10,489
Pre-tax profit	90,687	107,041	123,474	126,488	136,403
Tax	-14,970	-16,347	-21,608	-25,298	-25,170
Extraord./Min.Int./Pref.div.	0	0	0	0	0
Reported net income	75,717	90,693	101,866	101,190	111,233
Adjusted earnings	75,717	90,693	101,866	101,190	111,233
Adjusted EBIT	89,340	110,041	129,186	130,906	136,412
Growth Rates (%)					
EPS (adjusted)	43.0	19.8	12.3	-0.7	9.9
EBIT (adjusted)	41.0	23.2	17.4	1.3	4.2
Sales	27.5	23.0	34.7	-7.2	-4.2
Cash Flow (RsM)					
Operating cash flow	144,871	117,189	174,210	148,026	168,658
Depreciation/amortization	37,235	34,009	38,991	35,195	44,220
Net working capital	31,919	-7,514	33,354	11,641	13,206
Investing cash flow	-42,746	2,515	-125,346	-74,000 74,000	-70,000
Capital expenditure	-37,669	-126,361	-84,640	-74,000	-70,000
Acquisitions/disposals	-5,035	128,876	-40,706	0 <b>-3,001</b>	0 000
Financing cash flow Borrowings	<b>-37,120</b> 6,620	-176,268	-29,790		<b>-22,080</b> -764
Dividends paid	-11,917	41,174 -15,885	-14,117 -15,672	30,889 -15,672	-17,240
Change in cash	65,005	-56,565	19,075	71,025	76,579
	00,000	00,000	10,070	71,020	70,070
Balance Sheet (RsM)	004 100	710 000	00E 112	000 740	1 000 500
Total assets	804,198	718,893	<b>905,113</b> 33,267	996,742	1,086,589
Cash & cash equivalent Net fixed assets	70,756	14,192 441,935	33,267 487,584	104,292 526,389	180,871 552,170
Total liabilities	349,582 <b>401,829</b>	<b>432,909</b>	532,936	520,369 <b>539,048</b>	534,901
Debt	187,846	218,656	204,539	217,211	212,371
Shareholders' funds	402,369	285,980	372,173	457,691	551,684
Profitability/Solvency Ratios (%)	· ·	•	·	·	•
EBITDA margin adjusted	19.2	17.7	15.4	16.4	18.6
ROE adjusted	20.3	26.4	31.0	24.4	22.0
ROIC adjusted	19.3	21.2	21.3	19.8	19.6
Net debt to equity	29.1	71.5	46.0	24.7	5.7
Total debt to capital	31.8	43.3	35.5	32.2	27.8
. Sta. dobt to oupitul	01.0	70.0	00.0	02.2	27.0

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at +852-2501-2791.




# RIL 2QFY07 Results — Key Highlights

Figure 1. RIL 2QFY07 Results (Rupees in Millions)

Year to 31 Mar	2QFY06	2QFY07	% уоу	Comments
Net sales	207,170	284,740	37.4%	Driven by increase in volumes and absolute prices in petchem and refining
Expenditure:	•	·		
Inc/dec in stock	(7,990)	(8,730)	9.3%	
Raw materials - external purchases	152,280	223,850	47.0%	Higher price for crude and other feedstock
Staff cost	2,590	2,840	9.7%	Down on a sequential basis
Other expenditure	23,170	21,130	-8.8%	Decrease on account of lower sales tax incurrence on domestic retail sales
Total	(170,050)	(239,090)	40.6%	
EBITDA	37,120	45,650	23.0%	Higher than expected, driven mainly by a strong petchem quarter
EBITDA margins	17.9	16.0	-189bps	
Interest	(2,220)	(2,780)	25.2%	
Depreciation	(8,040)	(10,180)	26.6%	Higher due to commissioning of new petchem/polyester capacities during the quarter
Non-op income	2,220	220	-90.1%	Lower on account of lower cash balance
PBT	29,080	32,910	13.2%	
Tax	(2,510)	(3,770)		
PAT after current tax	26,570	29,140	9.7%	
Provision for deferred tax	(1,760)	(2,050)		
Tax rate (%)	14.7	17.7	300bps	FY07 run-rate as expected and in line with increase in MAT during the year
Net profit (reported)	24,810	27,090	9.2%	
Source: Company Reports and Citigroup	Investment Resea	rch		

Figure 2. RIL — Quarterly EBIT Break-up (Rupees in Millions)

Petrochemicals contributed 49% to group profitability, up from 32% in 1Q (an absolute increase of Rs6.8bn)



Source: Company Reports and Citigroup Investment Research

Figure 3. RIL 2QFY07 Segmental	l Profitability (R	upees in Milli	ons)		
Year to 31 Mar Revenues	2QFY06	1QFY07	2QFY07	%Y <sub>0</sub> Y	Comments
Petrochemicals	81,710	97,870	108,740	22 10/	Higher absolute prices and volume growth in polyester and polymers (new
% of total	30.0%	31.4%	31.4%	33.1 /	capacities commissioned and absorbed)
				24.00/	Higher absolute prices + higher throughput
Refining	185,950	208,620	232,080	24.0%	Thigher absolute prices i higher throughput
% of total	68.3%	66.9%	67.0%	05.00/	
Others	4,410	5,300	5,550	25.9%	
% of total	1.6%	1.7%	1.6%		
Intra - segment sales/transfers	43,140	50,130	50,870		
Excise Duties recovered	21,760	16,440	10,760		Decline in excise duties due to lower retail sales of diesel
Net sales	207,170	245,220	284,740	37.4%	
PBIT					
Petrochemicals	12,790	10,870	17,640	37.9%	Higher polymer margins, stable polyester margins combined with volume growth
% of total	41.8%	31.9%	48.8%		
Margin	15.7%	11.1%	16.2%	0.6%	Margin improvement primarily driven by polymers and fiber intermediates
Refining	15,320	20,350	14,890	-2.8%	Lower GRMs offset by lower retail fuel losses and higher thruput
% of total	50.1%	59.7%	41.2%		
Margin	8.2%	9.8%	6.4%	-1.8%	
Others	2,470	2,840	3,650	47.8%	
% of total	8.1%	8.3%	10.1%		
Margin	56.0%	53.6%	65.8%	9.8%	
Total PBIT	30,580	34,060	36,180	18.3%	
Source: Company Reports and Citigro	•	•	•		

	Units	Q1FY06	Q2FY06	Q3FY06	Q4FY06	Q1FY07	Q2FY07	Comments
Singapore complex spreads	US\$/bbl	7.4	8.2	6.0	4.6	9.0	4.8	
RIL reported GRMs	US\$/bbl	11.4	10.4	9.1	10.4	12.4	9.1	From company reports
Mktg. losses/bbl of diesel sold	US\$/bbl	(0.0)	(3.2)	3.6	(1.9)	(13.3)	(11.1)	Sequential decline on account of significant market share reductio
Effective marketing discount	US\$/bbl	(0.0)	(0.3)	0.5	(0.3)	(1.6)	(0.3)	Adjusted for proportion of retail sales to total
RIL clean GRMs	US\$/bbl	11.4	10.7	8.6	10.7	14.0	9.4	Arrived at by adding back the effective marketing discount/losses Narrowed slightly in 2Q but still healthy; lack of inventory losses wa
Differential vis-à-vis clean GRMs	US\$/bbl	4.0	2.5	2.6	6.1	5.0	4.6	remarkable
Crude throughput	MMT	7.9	8.0	6.7	7.9	7.5	8.2	Recovered post the planned shutdown in 1Q

	Q1FY06	Q2FY06	Q3FY06	Q4FY06	Q1FY07	Q2FY07	%YoY	%QoQ	Comments
PSU	1.9	1.7	0.7	1.1	0.7	0.7	-57.6%	0.0%	On the decline as new PSU capacities commission
Captive	1.6	1.7	1.2	1.8	1.7	1.7	3.0%	0.0%	·
Retail	0.6	0.6	0.9	1.1	0.9	0.2	-68.8%	-77.8%	Conscious reduction in market share due to marketing losses
Industrial sales/ Others	1.3	1.3	1.1	1.2	1.1	1.0	-25.4%	-9.1%	•
Exports	2.5	2.7	2.5	3.2	3.5	5.2	91.9%	48.6%	Trend of retail sales being substituted by exports continues
Total	7.8	8.0	6.3	8.4	7.9	8.8	10.1%	11.4%	<b>3</b>

Figure 6. Differential Between Reported GRMs and Singapore GRMs

Source: Company Reports and Citigroup Investment Research

### Volume growth provides some sustainability to petrochemical performance

During 1HFY07, the production volumes of polyester products and intermediates was up by a meaningful 32% yoy and 20% yoy respectively, reflecting almost full utilization of the recently commissioned POY/PSF and PTA capacities (commissioned in July 2006). Meanwhile, the production growth in polymers was a more muted 7% during 1H , a reflection of a moderate demand growth (1% yoy) and despite capacity expansion and better demand growth in PP (9% yoy).


### **Earnings Revision**

We have marginally increased our earnings by 3-4% primarily to reflect the lower-than-earlier-anticipated losses on retail petroleum marketing based on lower auto fuel marketing volumes.

Year to	Net Profit (R	ts Mils.)	Dilut	ed EPS (Rs)	D	ividend Per Sh	nare (Rs)
31-Mar	Old	New	Old	New	% Chg	Old	New
2007E	98,424	101,866	70.65	73.12	3.5%	10.00	10.00
2008E	97,775	101,190	70.18	72.64	3.5%	10.00	10.00
2009E	111,224	111,233	79.84	79.85	0.0%	11.00	11.00

Figure 8. RIL Operational Parameters — Petrochemicals and E&P Business											
Year to 31 Mar Production	Units	Q1FY06	Q2FY06	Q3FY06	Q4FY06	Q1FY07	Q2FY07	%Y <sub>0</sub> Y	%QoQ		
Panna-Mukta	-	000 000	005.050	410.007	400 400	001 007	400 F1C	1 . 70/	10.00/		
- Crude	Tonnes	360,288	365,052	412,327	432,429	381,997	422,516	15.7%	10.6%		
- Gas	mscm	333	299	331	483	347	360	20.4%	3.7%		
<u>Tapti</u>											
- Gas	mscm	540	605	573	579	522	420	-30.6%	-19.5%		
	_						224.222	0.4.00/	0.00/		
Polyester (PFY, PSF, PET)	Tonnes	279,000	270,000	284,000	296,000	361,000	364,000	34.8%	0.8%		
Fiber intermediates (PX, PTA, MEG)	Tonnes	795,000	813,000	712,000	900,000	886,000	1,057,000	30.0%	19.3%		
Polymers (PE, PP, PVC)	Tonnes	463,000	485,000	391,000	506,000	469,000	563,000	16.1%	20.0%		
	_						227 222	0.00/	10.10/		
Ethylene	Tonnes	212,000	209,000	266,000	153,000	162,000	227,000	8.6%	40.1%		
Propylene	Tonnes	100,000	100,000	129,000	69,000	77,000	110,000	10.0%	42.9%		
Industry demand											
Industry demand	1000 T	420	405	400	401	F10	454	-2.4%	-11.5%		
Polyester (PFY, PSF, PET)	'000 Tonnes	438	465	463	491	512					
Polymers (PE, PP, PVC)	'000 Tonnes	857	1,130	899	1085	977	1030	-8.9%	5.4%		
Source: Company Reports and Citigroup In	vestment Research										

Figure 9. PE-Naphtha Differential (US\$/MT)



Source: Datastream

Figure 11. POY-Naphtha Differential (US\$/MT)






Figure 10. PP-Naphtha Differential (US\$/MT)




Source: Datastream

Figure 12. PSF-Naphtha Differential (US\$/MT)



Source: Datastream

Figure 13. Relative Price Performance



Source: Datastream

Figure 14. Price Performance (%)

	3M	6M	12M
Absolute	20.3	35.5	169.1
Relative	-4.3	24.6	70.0

Source: Datastream

### **Reliance Industries**

### **Company Description**

Reliance Industries is a conglomerate with interests in upstream oil & gas (E&P), refining, and petrochemicals. It is building a super-size refinery project through its 75% subsidiary (RPL) and will be undertaking development of a large gas find in KG basin over the next 2-3 years. RIL is foraying into organized retailing and has plans to undertake SEZ projects over the medium to long term.

#### **Investment Thesis**

We rate RIL Hold/Low Risk (2L) with a target price of Rs1,150. Factors such as diversity of revenues, integration across product chains and volume growth should help RIL tide over downturns in product cycles. The volume expansion in the petrochemical and polyester chain should partly offset margin pressure in the medium term. Significant gains from the foray into retail marketing of petroleum products, while adversely affecting short-term profitability, would likely reduce dependence on the export markets and cushion volatility in the refining cycle. We expect regional refining margins to remain robust, with RIL enjoying a premium for its superior complexity. E&P looks set to become meaningful in the next 3-4 years as the KG D6 field commences gas production. Upgrade of reserves in KG basin adds to the value, although the NAV of the gas find is dependent on development capex as well as the demand profile from anchor customers. Notwithstanding the step-up in E&P's contribution from FY09E, RIL will likely report muted earnings growth in FY06-09E on account of the current cyclical peak in the refining and petrochemicals business. We believe the current valuations factor in a large part of the core business fundamentals as well as value accretion from higher KG gas reserves. While the new initiatives of organized retailing and SEZs are potential growth opportunities, we believe value accretion is still some time away.

### Valuation

Our target price is based on a sum-of-the-parts value: (1) RIL's core petrochem and downstream oil business valued on an EV/EBITDA of 6.0x for FY08E, in line with the regional chemicals and refining peers. (2) Our March 2007E DCF value for the KG-gas is Rs181/share based on recoverable reserves, capex, gas realizations. (3) Valuation contribution for NEC-25 is arrived at by applying the KG basin benchmark (EV/boe of US\$2.1) to NEC's estimated recoverable reserves of 2.7tcf. (4) Oil discovery in KGIII 6 has been valued at US\$5/boe applied to estimated reserves of 500m bbl at 50% recovery probability. (5) Investment in IPCL and RPL has been valued at 25% discounts to target prices to reflect the holding-company structure. (6) Treasury stock has been valued at RIL's target price.

Our target price is also based on a FY08E P/E of 14.0-14.5x, in line with the current benchmark Indian index (Sensex), plus the value of the treasury stock. We believe RIL should trade in line with the broad market, as significant value accretion from investment in listed subsidiaries and E&P assets offsets the cyclicality of its earnings.

### **Risks**


We rate RIL Low Risk, as opposed to Medium Risk suggested by our quantitative risk-rating system, which tracks 260-day historical share-price volatility. Diversified earnings and significant value contribution from the emerging E&P business and investment in listed subsidiaries have led to qualitative changes in the value constituents of the stock. Risks that could impede the stock from reaching our target price are: (1) RIL's margins are exposed to the global petrochemical and refining cycles. (2) The group could be asked to offer larger discounts on products sold to oil public sector units. (3) Any delay in the key KG D6 gas and refinery expansion project. (4) The organized retailing and SEZ initiatives would call for significant investment in RIL's non-core areas. Upside risks that would result in the stock exceeding our target price include: (1) Further tightening in the refinery demand-supply scenario. (2) Increase in 1P/2P reserves in KG basin or increase in development capex could result in further value accretion. (3) Higher-than-expected oil reserves in KG Basin blocks. (4) New oil and gas discoveries. (5) Faster-than-expected implementation of the organized retailing foray and SEZs. (6) Earlier-thanexpected value realization from the new initiatives.

### Analyst Certification Appendix A-1

We, Rahul Singh and Pradeep Mirchandani, CFA, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### IMPORTANT DISCLOSURES

### Reliance Industries (RELI.BO)



A director of Reliance Industries serves as a director on Citigroup's International Advisory Board.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Reliance Industries. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Reliance Industries.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Reliance Industries.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Reliance Industries in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Reliance Industries.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Reliance Industries.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Reliance Industries.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 30 September 2006	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (2914)	46%	40%	14%
% of companies in each rating category that are investment banking clients	44%	43%	32%
India Asia Pacific (105)	59%	16%	25%
% of companies in each rating category that are investment banking clients	52%	65%	38%

**Guide to Fundamental Research Investment Ratings:** 

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12

months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks). Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

### OTHER DISCLOSURES

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of a public offering of equity securities of Reliance Industries.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of fixed income securities of Reliance Industries.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Reliance Industries. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Reliance Industries.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Reliance Industries.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. In producing Products, members of the Firm's research department may have received assistance from the subject company(ies) referred to in the Product. Any such assistance may have included access to sites owned, leased or otherwise operated or controlled by the issuers and meetings with management, employees or other parties associated with the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka

Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19. Mobile on the Park, 157 lambton Quay, Wellington, The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2006 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST